Prospect Venture Partners is a venture capital firm managing over $1 billion in capital, focusing on biopharmaceutical and medical device companies. The firm invests across various stages, from seed to growth, targeting enterprises with proprietary products and innovative technologies. Their typical investment rounds include Series A, B, C, and beyond, supporting companies with diverse development and financing needs.
Notable portfolio companies include Amicus Therapeutics, Jazz Pharmaceuticals, NGM Biopharmaceuticals, and Element Science. The firm prides itself on partnering with exceptional entrepreneurial teams committed to excellence. Prospect Venture Partners offers unique value-add services, leveraging their extensive industry expertise to help portfolio companies achieve significant returns.
Prospect Venture Partners - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Total Investments42
Current Portfolio Count12
Total Portfolio Exits4
Top Investment Stages
Series B17 (42.5%)
Series A12 (30.0%)
Series C6 (15.0%)
Series D3 (7.5%)
Series Unknown2 (5.0%)
Stage Mix
Series B 43%Series A 30%Series C 15%Series D 8%Series Unknown 5%
Concentration shown as share of disclosed investments by stage.
Prospect Venture Partners - Classification
- NAICS
- 520000Finance and Insurance
- 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
- 523900Other Financial Investment Activities
- 523990All Other Financial Investment Activities
- 523999Miscellaneous Financial Investment Activities
- SIC
- 6700Holding And Other Investment Offices
- 6790Miscellaneous Investing
- 6799Investors, Not Elsewhere Classified
Show 6 more industry codes
- NAICS
- 525000Funds, Trusts, and Other Financial Vehicles
- 523910Miscellaneous Intermediation
- 523940Portfolio Management and Investment Advice
- SIC
- 6000Depository Institutions
- 6720Investment Offices
- 6722Management Investment Offices, Open-end